Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

Late-stage studies of AstraZeneca’s COVID-19 vaccine candidate are on temporary hold while the company investigates whether a recipient’s “potentially unexplained” illness is a side effect ...

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to ...

AstraZeneca and Honeywell are developing MDIs that will use a new propellant called HFO-1234ze, which, according to the company, has 99.9% less Global Warming Potential (GWP) than existing ...

Concerned that the nation’s health leadership is casting unfounded doubt on the safety of well-studied vaccines and may take action to curb their use, a group of public health experts is working ...

Gifting allows recipients to access the article for free. Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 vaccine as a post-approval commitment, a source familiar with the ...

Several recent studies suggest that the vaccines reduce the risk of dementia in older adults, but key questions remain, including: How the vaccines might work to stop or delay the condition ...

Prevention and vaccines Vaccination is the safest and most effective way to prevent measles. The measles, mumps, rubella (MMR) vaccine plays a vital role in safeguarding the health of patients ...

The agreement with AstraZeneca expands on the strategic partnership between the two companies announced in 2021 and aims to leverage Tempus’ AI-enabled platform and vast repository of multimodal ...